England

NICE Backed Acalabrutinib and Venetoclax Without Obinutuzumab, and the Omission Is the Decision

by
NICE Backed Acalabrutinib and Venetoclax Without Obinutuzumab, and the Omission Is the Decision

AMPLIFY tested acalabrutinib and venetoclax with and without obinutuzumab. NICE recommended the doublet, which is a decision about infusions.